Table of Contents
Epidemiology and Etiology of Hemolytic Disease of the Newborn
Fetal hemolytic disease (FHD) is more common amongst Caucasians than African-American babies.
Incompatibility between maternal and fetal blood is the main cause of FHD. This incompatibility can be either AB0 blood group incompatibility or Rh factor incompatibility. Of these, Rh factor incompatibility is more common and more severe.
Rh factor incompatibility is reported commonly when the mother is Rh negative while the fetus is Rh positive. This incompatibility is due to several antigens, the D antigen being the chief culprit while other antigens like c, C, E, and e may also be responsible. Maternal immune system responds to these antigens by forming IgM antibodies during the first encounter and these IgM antibodies do not cross the placenta. However, a subsequent exposure to the antigen triggers release of IgG antibodies by the maternal immune system and these antibodies travel across the placenta to the fetal circulation, target the fetal RBCs causing lysis and FHD.
Maternal sensitization can occur at various times e.g. when delivering an Rh negative fetus or during a prenatal bleed or miscarriage or after receiving a blood transfusion or when the woman undergoes chorionic villus sampling or a procedure to terminate the pregnancy. A small amount of fetal blood entering the maternal blood stream is sufficient to cause maternal sensitization.
FHD secondary to AB0 incompatibility is less severe as compared to Rh incompatibility as fetal RBCs have fewer AB0 blood group antigens than adults. Also, unlike Rh antigens, various fetal tissues express AB0 blood group antigens and so there is a lesser possibility for anti-A and anti-B to bind to the fetal red blood cell antigens.
Minor blood group incompatibility is a very rare cause of FHD and occurs due to E, c, Kell, Kidd or Duff antigens. The signs and symptoms of FHD secondary to minor group incompatibility are similar to those in Rh incompatibility although hemolysis in anti-Kell disease can be more severe due to suppression of RBCs or excessive RBC hemolysis.
Clinical Presentation of Hemolytic Disease of the Newborn
Clinical presentation of FHD depends on the rate of hemolysis and can be classified as mild, moderate or severe.
When the rate of RBC hemolysis is well tolerated by the fetus, the symptoms and signs of FHD are mild. In the neonatal period, clinical features of mild anemia and hyperbilirubinemia can be noted and they usually resolve without intervention.
When the rate of RBC hemolysis is moderate during pregnancy, the fetal bilirubin levels are low as the placenta continues to filter the bilirubin from the fetal circulation. However, after birth, the immature neonatal liver cannot metabolize the excessive amount of bilirubin leading to hyperbilirubinemia and accumulation of bilirubin in the plasma and tissues.
Excessive bilirubin accumulation in the brain results in a condition called kernicterus, which can be potentially fatal or can lead to neurological deficits if the baby survives.
When the rate of RBC hemolysis in utero is excessive, rapid and prolonged, it leads to severe fetal anemia with erythroblasts (immature RBCs) flowing into the fetal circulation. The fetal liver and spleen overwork to compensate for the loss of the RBCs leading to hepatosplenomegaly, and later to hepatic dysfunction.
Eventually, edema of fetal tissues (also called hydrops fetalis associated with low serum albumin levels) develops leading to cardiac and respiratory failure followed by fetal demise.
A baby born with FHD can present with hyperbilirubinemia (jaundice), coagulopathies, hypoglycemia (secondary to islet cell hyperplasia and hyperinsulinemia).
Diagnosis of Hemolytic Disease of the Newborn
As several conditions can mimic the presentation of FHD, the diagnosis depends on detecting Rh or AB0 incompatibility.
During pregnancy, the diagnosis is based on:
- History of sensitization in the mother during previous pregnancy or current pregnancy
- Evaluation of maternal blood group and Rh factor
- Atypical antibodies test (AAT) results
- Direct Coombs test in an Rh negative mother. If anti-D is found, then Amniocentesis is performed to harvest fetal cells and detect the Rh status of the fetus.
- If the fetus is detected to be Rh positive, then it is monitored for the development of FHD by scheduling fetal ultrasound at regular intervals and monitoring maternal anti-D levels. An increase in the titer of anti-D titer is an indication of active RBC hemolysis.
After delivery, the diagnosis and management is based on fetal testing:
- Complete blood count and reticulocyte count
- Serum bilirubin level
- Blood group and type
- Peripheral smear
- Coagulation profile
Laboratory findings in AB0 incompatibility which differ from Rh incompatibility:
- Peripheral smear shows microspherocytosis
- Direct Coombs’ test may be weakly positive
- Mean corpuscular volume
- Alpha thalassemias
- RBC enzyme disorders like Glucose-6-phosphate or pyruvate kinase deficiency
- RBC membrane disorders like hereditary spherocytosis
- RBC hemolysis secondary to drugs, sepsis, TORCH infection, Parvovirus B19 infection
Treatment of Hemolytic Disease of the Newborn
Fetal anemia is monitored in cases where FHD is detected. In utero blood transfusion may be required repeatedly to treat the anemia. If there is evidence of fetal distress, then labor may have to be induced to prevent worsening of FHD.
- Neonate may require frequent feeding as well as intravenous fluid replacement.
- Exchange blood transfusion is indicated in severe hyperbilirubinemia to remove the excess bilirubin and antibodies.
- Phototherapy helps to metabolize the excess bilirubin in the tissues. Care of the neonatal eyes is vital to prevent retinal damage during phototherapy.
- Intravenous immunoglobulins are administered to prevent neonatal RBC destruction.
- Inotropic agents may be required along with intravenous fluids to treat hypotension.
- Antibiotics if there is concomitant neonatal sepsis.
- Oxygen and surfactant with mechanical ventilation may be required in neonates with immature lungs.
Prognosis and Prevention of Hemolytic Disease of the Newborn
Prognosis of FHD is variable as some babies with mild disease are asymptomatic while severe hemolysis with fetal hydrops can lead to intra-uterine or neonatal fetal death unless detected and treated early.
FHD is a preventable disease. Counseling Rh negative women, antenatal education and antenatal testing with indirect Coombs test plays an important role in its prevention. An Rh negative woman should be administered RhoGam around the 28th week of pregnancy followed by a second dose within 72 hours of delivery if the baby is Rh positive. However, if the baby is Rh negative then the second dose needs not be administered.